martes, 23 de septiembre de 2014

The NCI RAS Program - National Cancer Institute

The NCI RAS Program - National Cancer Institute

National Cancer Institute at the National Institutes of Health

The NCI RAS Program

Collaborate with RAS Experts, Find Reagents & Tools, Solve the RAS Challenge

The NCI RAS Program

NCI established the RAS Program to explore innovative ways to attack the proteins encoded by mutant forms of the RAS genes or other vulnerabilities as a way to treat key types of cancer, including pancreatic, lung, and colorectal cancers. We encourage you to collaborate with RAS experts, find and use reagents and tools, and help us solve the RAS challenge.

The NCI RAS Program At-a-Glance

  • NCI’s goal is to attack RAS-driven cancers through an integrated, collaborative program that hopefully will result in effective new therapies for patients with tumors that have RAS mutations.
  • The RAS Program is based at the NCI Frederick National Laboratory for Cancer Research (FNL)in Frederick, MD.
  • Existing FNL funding has been redirected to support the RAS Program.
  • Dr. Frank McCormick leads the program’s scientific efforts.

RAS Central

Post comments, ask questions, and share information with RAS experts on the RAS Central page. Join the scientific discussion!

What’s Happening Now 

2014 UCSF Seminar Videos Posted

Ten presentations from the symposium "Targeting RAS Now for Future Cancer Therapy," held at the University of California, San Francisco, June 19th and 20th, 2014, are now available.

New Message from Dr. Frank McCormick

Dr. Frank McCormick discusses his vision for the NCI RAS Program and encourages collaboration among the 1,500 labs worldwide that work on the RAS pathways every day.

New Commentary from Dr. Channing Der

Dr. Der asks why the four RAS proteins are implicated in different human cancers in his new, in-depth commentary.

RAS Pathways & Reagents

Obtain unique and powerful RAS and RAS pathway reagents developed at FNL. 
  • RAS Entry Clone Collection 1
    • 15 RAS pathway genes
    • Open and closed formats
    • Plasmid DNA and glycerol stocks of E. coli DH10B harboring each plasmid
  • KRAS Entry Clone Collection 1
    • Wild-type KRAS and 10 point mutations
    • Open and closed formats
    • Plasmid DNA and glycerol stocks of E. coli DH10B harboring each plasmid

No hay comentarios:

Publicar un comentario